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AbstrACt
Objectives In this study, we analysed patient information 
leaflets (PILs) of intranasal corticosteroid sprays (INCS) 
of different manufacturers in the UK to determine if 
instructions for the use of INCS are complete and uniform.
setting PILs of all INCS of all manufacturers, available for 
patients in the UK, were collected from the British National 
Formulary website and the Medicines and Healthcare 
products Regulatory Agency website. All instructions in 
these PILs were analysed.
Participants We identified PILs of INCS from 21 different 
manufacturers, available for patients in the UK.
results We analysed the instructions for the use of INCS 
in 21 different PILs and there is large variation in the PIL 
instructions for the technique of using INCS across PILs.
Conclusion Complete and uniform instructions for the 
use of INCS are lacking in PILs for registered preparations 
in the UK. Structured and standardised instructions to be 
used by both professionals and patients are essential in 
order to optimise daily use of INCS.
IntrOduCtIOn 
Allergic rhinitis (AR) is a common condition 
in both children and adults, with prevalences 
ranging from 9% in children aged 6–7 years 
and 27% in adults aged 22–44 years.1 2 The 
recommended pharmacological treatment 
of AR includes antihistamines and intranasal 
corticosteroids. Antihistamines are used in 
oral and intranasal dosage forms. Corticoste-
roids suppress inflammation and are avail-
able in oral dosage forms, but due to systemic 
adverse events (AEs), intranasal corticoste-
roids are preferred.3 4 Intranasal corticoste-
roids are available in sprays or drops and 
in most patients sprays are prescribed. An 
adequate technique of using intranasal corti-
costeroid sprays (INCS) is imperative: the 
technique may affect efficacy, AEs and compli-
ance.5 Little data are available on the associa-
tion between the quality of the techniques of 
using INCS and its safety and efficacy.
To our knowledge no standardised proto-
cols are available with instructions for use of 
INCS. Patient information leaflets (PILs) are 
the only source of information about instruc-
tions, in addition to the instructions given by 
the doctor, nurse or pharmacist. We explored 
which instructions for the use of INCS are 
provided in PILs by the different manufac-
turers in the UK.
MethOds
PILs of all INCS of all manufacturers, avail-
able for patients in the UK, were collected 
from the British National Formulary website 
and the Medicines and Healthcare products 
Regulatory Agency website. These PILs are 
identical to what is provided to the patient in 
the medicine pack. The instructions included 
in these PILs were categorised in the consecu-
tive steps before, during and after administra-
tion of the INCS, as shown in table 1. For every 
PIL we evaluated whether it includes these 
steps and for each instruction we counted in 
how many of the PILs it was included. Missing 
instructions regarding before, during and 
after administration were coded as such and 
counted. Steps for priming and cleaning of 
strengths and limitations of this study
 ► This observational study evaluates all patient in-
formation leaflets (PILs) of intranasal corticosteroid 
sprays (INCS) available for patients in the UK.
 ► This is the first study that evaluates PILs of INCS on 
uniformity and completeness.
 ► All PILs are collected from the British National 
Formulary and Medicines and Healthcare prod-
ucts Regulatory Agency websites and each PIL is 
checked whether a specific instruction for use of the 
INCS is included.
 ► We do not know if administration of INCS depends 
on the instruction described in PILs.
 ► We did not collect data on instructions for the use of 
INCS given by doctors, nurses and pharmacists and 
whether the PILs are used during these instructions.
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the sprays are also mentioned in PILs of INCS, which can 
also be distinguished in consecutive steps. In this anal-
ysis, we only exemplify all steps for daily administration of 
INCS as mentioned in the PILs.
Patient and public involvement
Patients and public were not directly involved in this 
study.
results
We identified PILs of INCS from 21 different manufac-
turers (table 2). Table 1 shows how many PILs include 
instructions for each step, and table 2 shows an overview 
of each spray and whether the instruction is supplied. All 
PILs instruct to shake the bottle (step 1) and take the 
dust cap off (step 2) prior to use. Instructions for nose 
blowing, hand positioning, closing the nostril, head posi-
tioning, positioning of the spray, inhaling and exhaling, 
cleaning the nozzle, replacing the dust cap and storing of 
the spray (step 3 to step 12) varied or were not included.
In all 21 PILs one or more steps were missing. Instruc-
tions for nose blowing, positioning of the spray, exhaling, 
replacing the dust cap and storing were missing from 1, 
20, 3, 3 and 18 PILs, respectively. Instructions regarding 
hand positioning, closing the nostril, head positioning, 
inhaling and cleaning were conflicting across PILs (see 
table 1).
dIsCussIOn
This study shows that there is a large variation in the PIL 
instructions for the technique of using INCS across PILs 
of those sprays available for UK patients.
There has been little research on consistency and 
impact of instructions for use of INCS given by the doctor, 
nurse or pharmacist on patients’ use of these sprays and 
Table 1 Instructions for use of the 21 intranasal corticosteroid sprays studied
Moment Step Instruction Number
Prior to 
use
Step 1
Shaking
Shake the bottle 21
Step 2
Take off dust cap
Take off the dust cap 21
Step 3
Nose blowing
Blow the nose 20
No instruction 1
During 
use
Step 4
Hand position
A Forefinger and middle finger on both sides of the nozzle and 
thumb underneath the bottle
15
B Hold bottle as shown in the picture 9
Step 5
Closing nostril
A Put the tip of the nozzle into the nostril and close the other 
nostril
17
B Put the tip of the nozzle into the nostril 4
Step 6
Head position
A Slightly tilt forward 18
B Upright 3
Step 7
Position spray
Point the end of the nozzle slightly outwards, away from the 
centre ridge of the nose
1
No instruction 20
Step 8
Inhalation instruction
A Squirt a spray of mist in the nose while breathing in 18
B Squirt a spray of mist in the nose while breathing in is not 
necessary
3
Step 9
Exhalation instruction
Breathe out through the mouth. 18
No instruction 3
After use Step 10
Clean nozzle
A Wipe the nozzle with a tissue or handkerchief 18
B Wash the nozzle frequently with warm water. 3
Step 11
Replace dust cap
Replace the dust cap 18
No instruction 3
Step 12
Storage
Store the bottle in an upright position. 3
No instruction 18
Described are the consecutive steps before, during and after use of INCS, the specific instruction for a step and the number of PILs  wherein 
the specific instruction is described. Daily administration of INCS consists of 12 steps and for some steps different instructions are described.
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their clinical effectiveness. Nor has there been research 
on the role of PILs on these outcomes.
PILs fulfil a supporting role; information in PILs 
improve patients’ knowledge, but information needs 
to concise and precise and information needs to be 
accompanied by oral information.6 Different or missing 
instructions in PILs for the same product of different 
manufacturers can confuse the patient and healthcare 
professionals. Instructions for correct use of INCS is a 
joined task of doctor, nurse, pharmacist and manufac-
turer. We believe it is essential to provide uniform and 
complete instructions in PILs.
Benninger et al reviewed the literature on techniques 
of intranasal steroids and their efficacy and developed 
detailed instructions for administration of INCS, in order 
to reach highest efficacy and prevent side effects.7 They 
recommend to administer the nasal spray in a neutral 
head position, so to minimise spillage of the drug into 
the throat which may cause mucosal irritation and facili-
tate absorption of the drug via the gastrointestinal tract. 
To minimise the risk of epistaxis, a known AE of INCS, it 
is recommended to point the nozzle of the spray outward, 
away from the nasal septum.8
The set of instructions of Benninger et al provides a 
good basis for the development of uniform and complete 
instructions for the use of INCS.
A limitation of our study is that we did not collect data 
on instructions for the use of INCS given by doctors, 
nurses and pharmacists and whether the PILs are used as 
a guide during these instructions.
Furthermore, intranasal corticosteroids are also avail-
able in nasal drops. The instructions for administration 
of these intranasal corticosteroid drops differ from the 
instructions for administration of INCS and are therefore 
not included in this study.
In conclusion, complete and uniform instructions for 
the use of INCS are lacking in PILs for registered prepa-
rations in the UK. Patients sometimes have to change 
their INCS due to price differences, stock availability 
and, sometimes, efficacy. It is confusing that INCS have 
a completely different set of instruction. Structured and 
standardised instructions to be used by both professionals 
and patients are essential in order to optimise daily use of 
INCS in patients with AR.
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